Designation of Rovalpituzumab Tesirine (TBA) as an orphan drug - Abbvie Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods in Australia, including medicines, medical devices, and blood products. This legislation was introduced to address the need for a comprehensive regulatory framework that ensures the safety, quality, and efficacy of therapeutic goods available in the Australian market. The Act is administered by the Therapeutic Goods Administration, an agency within the Australian Department of Health, with the policy objective of protecting public health by regulating the supply and advertising of therapeutic goods. Under the authority of this Act, Rovalpituzumab Tesirine (TBA) has been designated as an orphan drug for the treatment of small cell lung cancer, facilitating its development and availability for a rare and underserved patient population.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) within the Department of Health, applies to therapeutic goods, including medicines, medical devices, blood, and tissues. The scope of this particular legislation pertains to the designation of Rovalpituzumab Tesirine (TBA) as an orphan drug for the treatment of small cell lung cancer. This legislation applies to the sponsor of the therapeutic good, in this case, Abbvie Pty Ltd. Orphan drug designation is a Commonwealth-wide measure that aims to encourage the development of treatments for rare diseases or conditions. The geographic reach of this Act is national, as it is a Commonwealth Act. There are no exclusions or exemptions specified in this particular legislation; however, the designation of a therapeutic good as an orphan drug does not exempt it from other regulatory requirements under the Therapeutic Goods Act 1989. The application of this Act may be extended or restricted through subordinate instruments, such as the Therapeutic Goods Regulations 1990, which provide further detail on the process for designating orphan drugs and the criteria that must be met.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") provides the framework for the regulation of therapeutic goods in Australia. Section 16J of the Therapeutic Goods Regulations 1990, as referenced in the document, empowers a Delegate to designate certain medicines as orphan drugs. In this instance, Section 16J(2) is invoked to designate Rovalpituzumab Tesirine (TBA) as an orphan drug for the treatment of small cell lung cancer, effective from 20 May 2017. This designation is critical as it opens pathways for incentives and support to encourage the development of treatments for rare diseases. The obligations imposed by this designation primarily fall on the sponsor, Abbvie Pty Ltd, as stated in the document. The sponsor is responsible for ensuring that Rovalpituzumab Tesirine (TBA) meets all regulatory standards for therapeutic goods. This includes providing adequate data and evidence to support the drug's safety, efficacy, and quality. Additionally, the sponsor must comply with all ongoing requirements for reporting and monitoring the drug's performance in the market, ensuring it continues to meet the necessary standards post-approval. Failure to comply with the obligations and requirements set forth by the Therapeutic Goods Act and Regulations can result in significant consequences. For instance, if Abbvie Pty Ltd does not adhere to the reporting requirements or if the drug is found to be unsafe or ineffective, the Therapeutic Goods Administration (TGA) may take action. This could include withdrawing the drug from the market, imposing fines, or pursuing legal action against the sponsor. The Act does not specify maximum penalties within the document itself, but generally, penalties can be severe and may include substantial fines and imprisonment for individuals found guilty of serious offences under the Act.